314 related articles for article (PubMed ID: 24891519)
41. Selective inhibition of CCR7(-) effector memory T cell activation by a novel peptide targeting Kv1.3 channel in a rat experimental autoimmune encephalomyelitis model.
Li Z; Liu WH; Han S; Peng BW; Yin J; Wu YL; He XH; Li WX
J Biol Chem; 2012 Aug; 287(35):29479-94. PubMed ID: 22761436
[TBL] [Abstract][Full Text] [Related]
42. K
Veytia-Bucheli JI; Jiménez-Vargas JM; Melchy-Pérez EI; Sandoval-Hernández MA; Possani LD; Rosenstein Y
Cell Commun Signal; 2018 Aug; 16(1):45. PubMed ID: 30107837
[TBL] [Abstract][Full Text] [Related]
43. Affinity and selectivity of ShK toxin for the Kv1 potassium channels from free energy simulations.
Rashid MH; Kuyucak S
J Phys Chem B; 2012 Apr; 116(16):4812-22. PubMed ID: 22480371
[TBL] [Abstract][Full Text] [Related]
44. Molecular mechanism of the sea anemone toxin ShK recognizing the Kv1.3 channel explored by docking and molecular dynamic simulations.
Jin L; Wu Y
J Chem Inf Model; 2007; 47(5):1967-72. PubMed ID: 17718553
[TBL] [Abstract][Full Text] [Related]
45. Vm24, a natural immunosuppressive peptide, potently and selectively blocks Kv1.3 potassium channels of human T cells.
Varga Z; Gurrola-Briones G; Papp F; Rodríguez de la Vega RC; Pedraza-Alva G; Tajhya RB; Gaspar R; Cardenas L; Rosenstein Y; Beeton C; Possani LD; Panyi G
Mol Pharmacol; 2012 Sep; 82(3):372-82. PubMed ID: 22622363
[TBL] [Abstract][Full Text] [Related]
46. The voltage-gated potassium channel K
Tajti G; Wai DCC; Panyi G; Norton RS
Biochem Pharmacol; 2020 Nov; 181():114146. PubMed ID: 32653588
[TBL] [Abstract][Full Text] [Related]
47. Blockade of Kv1.3 channels ameliorates radiation-induced brain injury.
Peng Y; Lu K; Li Z; Zhao Y; Wang Y; Hu B; Xu P; Shi X; Zhou B; Pennington M; Chandy KG; Tang Y
Neuro Oncol; 2014 Apr; 16(4):528-39. PubMed ID: 24305723
[TBL] [Abstract][Full Text] [Related]
48. Structural basis of a potent peptide inhibitor designed for Kv1.3 channel, a therapeutic target of autoimmune disease.
Han S; Yi H; Yin SJ; Chen ZY; Liu H; Cao ZJ; Wu YL; Li WX
J Biol Chem; 2008 Jul; 283(27):19058-65. PubMed ID: 18480054
[TBL] [Abstract][Full Text] [Related]
49. Stichodactyla helianthus peptide, a pharmacological tool for studying Kv3.2 channels.
Yan L; Herrington J; Goldberg E; Dulski PM; Bugianesi RM; Slaughter RS; Banerjee P; Brochu RM; Priest BT; Kaczorowski GJ; Rudy B; Garcia ML
Mol Pharmacol; 2005 May; 67(5):1513-21. PubMed ID: 15709110
[TBL] [Abstract][Full Text] [Related]
50. A potent and Kv1.3-selective analogue of the scorpion toxin HsTX1 as a potential therapeutic for autoimmune diseases.
Rashid MH; Huq R; Tanner MR; Chhabra S; Khoo KK; Estrada R; Dhawan V; Chauhan S; Pennington MW; Beeton C; Kuyucak S; Norton RS
Sci Rep; 2014 Mar; 4():4509. PubMed ID: 24676092
[TBL] [Abstract][Full Text] [Related]
51. K+ channel blockers: novel tools to inhibit T cell activation leading to specific immunosuppression.
Panyi G; Possani LD; Rodríguez de la Vega RC; Gáspár R; Varga Z
Curr Pharm Des; 2006; 12(18):2199-220. PubMed ID: 16787250
[TBL] [Abstract][Full Text] [Related]
52. Toxins Targeting the Kv1.3 Channel: Potential Immunomodulators for Autoimmune Diseases.
Zhao Y; Huang J; Yuan X; Peng B; Liu W; Han S; He X
Toxins (Basel); 2015 May; 7(5):1749-64. PubMed ID: 25996605
[TBL] [Abstract][Full Text] [Related]
53. Mutating a critical lysine in ShK toxin alters its binding configuration in the pore-vestibule region of the voltage-gated potassium channel, Kv1.3.
Lanigan MD; Kalman K; Lefievre Y; Pennington MW; Chandy KG; Norton RS
Biochemistry; 2002 Oct; 41(40):11963-71. PubMed ID: 12356296
[TBL] [Abstract][Full Text] [Related]
54. Lovastatin blocks Kv1.3 channel in human T cells: a new mechanism to explain its immunomodulatory properties.
Zhao N; Dong Q; Qian C; Li S; Wu QF; Ding D; Li J; Wang BB; Guo KF; Xie JJ; Cheng X; Liao YH; Du YM
Sci Rep; 2015 Nov; 5():17381. PubMed ID: 26616555
[TBL] [Abstract][Full Text] [Related]
55. The toxin mimic FS48 from the salivary gland of Xenopsylla cheopis functions as a Kv1.3 channel-blocking immunomodulator of T cell activation.
Zeng Q; Lu W; Deng Z; Zhang B; Wu J; Chai J; Chen X; Xu X
J Biol Chem; 2022 Jan; 298(1):101497. PubMed ID: 34919963
[TBL] [Abstract][Full Text] [Related]
56. A designer ligand specific for Kv1.3 channels from a scorpion neurotoxin-based library.
Takacs Z; Toups M; Kollewe A; Johnson E; Cuello LG; Driessens G; Biancalana M; Koide A; Ponte CG; Perozo E; Gajewski TF; Suarez-Kurtz G; Koide S; Goldstein SA
Proc Natl Acad Sci U S A; 2009 Dec; 106(52):22211-6. PubMed ID: 20007782
[TBL] [Abstract][Full Text] [Related]
57. Solid phase synthesis, NMR structure determination of α-KTx3.8, its in silico docking to Kv1.x potassium channels, and electrophysiological analysis provide insights into toxin-channel selectivity.
Kohl B; Rothenberg I; Ali SA; Alam M; Seebohm G; Kalbacher H; Voelter W; Stoll R
Toxicon; 2015 Jul; 101():70-8. PubMed ID: 25953725
[TBL] [Abstract][Full Text] [Related]
58. Kv1.3 in psoriatic disease: PAP-1, a small molecule inhibitor of Kv1.3 is effective in the SCID mouse psoriasis--xenograft model.
Kundu-Raychaudhuri S; Chen YJ; Wulff H; Raychaudhuri SP
J Autoimmun; 2014 Dec; 55():63-72. PubMed ID: 25175978
[TBL] [Abstract][Full Text] [Related]
59. Ionisation behaviour and solution properties of the potassium-channel blocker ShK toxin.
Tudor JE; Pennington MW; Norton RS
Eur J Biochem; 1998 Jan; 251(1-2):133-41. PubMed ID: 9492277
[TBL] [Abstract][Full Text] [Related]
60. Synthetic hookworm-derived peptides are potent modulators of primary human immune cell function that protect against experimental colitis in vivo.
Smallwood TB; Navarro S; Cristofori-Armstrong B; Watkins TS; Tungatt K; Ryan RYM; Haigh OL; Lutzky VP; Mulvenna JP; Rosengren KJ; Loukas A; Miles JJ; Clark RJ
J Biol Chem; 2021 Jul; 297(1):100834. PubMed ID: 34051231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
